Recent Updates
Recently added Catalysts
CTMX

CytomX Therapeutics to Announce First Quarter 2018 Financial Results

Tuesday, May 1, 2018 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: SOUTH SAN FRANCISCO, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, plans to report first quarter 2018 financial results on

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
6.8%
average across 7 past catalysts
Cash runway
~54 mo
Minimal dilution risk
Lead asset
CX-2009
Phase 2 · Neoplasms

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, plans to report first quarter 2018 financial results on Wednesday, May 9, 2018, after the NASDAQ market close.
The company will not be conducting a conference call in connection with this financial results press release.
About CytomX Therapeutics
ShareAdd on Google
Tags: CTMX Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: May 1, 2018

Biotech snapshot

Cash runway
$330M liquidity · $6M/mo burn
~54 mo
Minimal dilution risk
Lead asset
CX-2009Phase 2
Neoplasms →

Catalyst track record

+53%
best trade around CTMX's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for CTMX.

See every catalyst's timing & PoA →